{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:25:21Z","timestamp":1761953121120,"version":"build-2065373602"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2556,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1111\/j.1529-8019.2008.00229.x","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T18:07:26Z","timestamp":1222884446000},"page":"S25-S29","source":"Crossref","is-referenced-by-count":3,"special_numbering":"supplement","title":["Efalizumab in the treatment of psoriasis: when comorbidity is an issue"],"prefix":"10.1155","volume":"21","author":[{"given":"Francesca","family":"Prignano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gionata","family":"Buggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torello","family":"Lotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"Suppl. 2","key":"10.1111\/j.1529-8019.2008.00229.x-BIB1","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/1523-1747.ep12371678","article-title":"T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation","volume":"101","author":"Strange","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00510050","article-title":"Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies","volume":"275","author":"Bos","year":"1983","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB4","first-page":"1619","article-title":"Altered expression of keratinocyte growth factor and its receptor in psoriasis","volume":"151","author":"Finch","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaad.2007.02.007","article-title":"Heart disease in psoriasis","volume":"57","author":"Kremers","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.297.4.362-a","article-title":"Psoriasis and risk of myocardial infarction","volume":"297","author":"Ludwig","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11926-006-0065-8","article-title":"Metabolic disorders in patients with psoriasis and psoriatic arthritis","volume":"8","author":"Mallbris","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.det.2005.05.017","article-title":"Stress and psychoneuroimmunologic factors in dermatology","volume":"23","author":"Urpe","year":"2005","journal-title":"Dermatol Clin"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(07)61129-5","article-title":"Current and future management of psoriasis","volume":"370","author":"Menter","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2006.00014","article-title":"Efalizumab in the treatment of psoriasis","volume":"10","author":"Gupta","year":"2006","journal-title":"J Cutan Med Surg"},{"issue":"Suppl. 2","key":"10.1111\/j.1529-8019.2008.00229.x-BIB13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2007.07762.x","article-title":"Efalizumab in routine use: a clinical experience","volume":"156","author":"Selenko-Gebauer","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00002018-200629010-00004","article-title":"Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability?","volume":"29","author":"Shear","year":"2006","journal-title":"Drug Saf"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB15","first-page":"66","article-title":"Disease concomitance in psoriasis: a clinical study of 61 cases","volume":"67","author":"Alexander","year":"2001","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2007.08068.x","article-title":"Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review","volume":"157","author":"Sterry","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1365-2133.2008.08548.x","article-title":"Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis","volume":"158","author":"Leonardi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study","volume":"157","author":"Gisondi","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0019-5359.16655","article-title":"Current status of TNF blocking therapy in heart failure","volume":"59","author":"Gupta","year":"2005","journal-title":"Indian J Med Sci"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumour necrosis factor therapy","volume":"20","author":"Desai","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1111\/j.1529-8019.2008.00229.x-BIB22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archderm.140.2.218","article-title":"Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis","volume":"140","author":"Krueger","year":"2004","journal-title":"Arch Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2008.00229.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2008.00229.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:10:50Z","timestamp":1738404650000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2008.00229.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2008.00229.x","relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"type":"print","value":"1396-0296"},{"type":"electronic","value":"1529-8019"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}